Invention Grant
- Patent Title: Oral quetiapine suspension formulations with extended shelf life and enhanced bioavailability
-
Application No.: US16784098Application Date: 2020-02-06
-
Publication No.: US10940155B2Publication Date: 2021-03-09
- Inventor: Carl Tierney , Andrew Gardner , Jan Pick-Katolik , Stacey Powell , Mark Foley , Laurence Ramsey , Andrew Hardeman
- Applicant: TLC THERAPEUTICS, LLC
- Applicant Address: US MD Owings Mills
- Assignee: TLC THERAPEUTICS, LLC
- Current Assignee: TLC THERAPEUTICS, LLC
- Current Assignee Address: US MD Owings Mills
- Agency: Nevrivy Patent Law Group P.L.L.C.
- Main IPC: A61K31/554
- IPC: A61K31/554 ; A61K9/107 ; A61K9/00 ; A61K47/24 ; A61J1/14 ; A61K45/06 ; B65B3/00 ; B65B7/28

Abstract:
A quetiapine fumarate composition for oral administration is provided comprising a pharmaceutically acceptable salt or solvate of quetiapine existing as a suspension in an aqueous carrier agent. The inventive liquid formulation demonstrates high bioavailability consistent with approved dosage forms, low agglomeration, reduced content of excipients commonly used in solid oral dosage forms and extended shelf life stability. Also provided is a method of manufacturing a liquid quetiapine suspension composition for oral administration and methods of administering therapeutically effective dosages of an oral liquid quetiapine suspension composition to patients in need thereof.
Public/Granted literature
- US20200179399A1 ORAL QUETIAPINE SUSPENSION FORMULATIONS WITH EXTENDED SHELF LIFE AND ENHANCED BIOAVAILABILITY Public/Granted day:2020-06-11
Information query